TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29566002

Group type: EXPERIMENTAL
Intervention: Cancer survivor vignette
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Cancer survivor during active follow-up
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Widowed respondents
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Timing of disclosure preference
Number of subjects: 593
Study: 27355508

Group type: EXPERIMENTAL
Intervention: ART delivery strategies during the postpartum period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adherence club model for long-term adherence and retention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of models of care
Number of subjects: 0
Study: 24499010

Group type: EXPERIMENTAL
Intervention: Auditory-evoked potentials (AEP) monitoring
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ramsay sedation scale (RSS) monitoring
Number of subjects: 37
Study: 22540372

Group type: EXPERIMENTAL
Intervention: Pancreatogastrostomy
Number of subjects: 360

Group type: COMPARATOR
Intervention: Pancreatojejunostomy
Number of subjects: 360
Study: 20795962

Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior fundoplication
Number of subjects: 103

Group type: COMPARATOR
Intervention: Laparoscopic posterior fundoplication
Number of subjects: 103
Study: 22642657

Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.05-0.22 U/kg)
Number of subjects: 20
Study: 15971720

Group type: EXPERIMENTAL
Intervention: Behavioral modification and antimuscarinics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuromodulation, denervation techniques, and bladder augmentation
Number of subjects: 0
Study: 12888148

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4607

Group type: COMPARATOR
Intervention: Sibrafiban
Number of subjects: 4607
Study: 10583435

Group type: EXPERIMENTAL
Intervention: E2 group (micronised oestradiol 2 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: E2 + P group (E2 + trimegestone 0.5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: E2 + D group (E2 + dydrogesterone 10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study: 8904612

Group type: EXPERIMENTAL
Intervention: Mefloquine 250 mg weekly for 4 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 1678925

Group type: EXPERIMENTAL
Intervention: Terazosin alone (1 to 80 mg/day)
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Propranolol (40 to 120 mg twice daily)
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Terazosin (5 mg) plus methyclothiazide (2.5 to 5 mg)
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Terazosin alone
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Terazosin plus methyclothiazide (2.5 mg)
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Terazosin plus methyclothiazide (5 mg)
Number of subjects: 1180
Study: 7160179

Group type: EXPERIMENTAL
Intervention: Vimule cap
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cavity Rim Cap (CRC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vimule cap (long-term users)
Number of subjects: 32
Study: 29671901

Group type: EXPERIMENTAL
Intervention: Doll Therapy (DT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hand warmers (active control)
Number of subjects: 29
Study: 28395936

Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study: 25519721

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian tools
Number of subjects: 0
Study: 23748507

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (EQW)
Number of subjects: 737

Group type: COMPARATOR
Intervention: Sitagliptin (sita)
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Both EQW and sita
Number of subjects: 737
Study: 20884959

Group type: EXPERIMENTAL
Intervention: Nalmefene 40 mg/day
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Nalmefene 20 mg/day
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 18416265

Group type: EXPERIMENTAL
Intervention: Acri. Smart IOL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AT-45 IOL
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: presbyLASIK
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (monofocal IOL)
Number of subjects: 45
Study: 16847590

Group type: EXPERIMENTAL
Intervention: Mantram intervention (n = 46)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Attention control group (n = 47)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Actual mantram practice
Number of subjects: 93
Study: 12838524

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 162

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 162
Study: 10811503

Group type: EXPERIMENTAL
Intervention: Eight-hour infusion of doxorubicin (arm A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous injection of doxorubicin (arm B)
Number of subjects: 120
Study: 8891089

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 1797602

Group type: EXPERIMENTAL
Intervention: 600 mg simethicone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7049301

Group type: EXPERIMENTAL
Intervention: Emepronium bromide (Cetiprin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31111801

Group type: EXPERIMENTAL
Intervention: 1-day AL initiation regimen (ALNCD + 30 mg oral aripiprazole for 1 day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 21-day AL initiation regimen (AL + 15 mg/day of oral aripiprazole for 21 days)
Number of subjects: 0
Study: 29849032

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) for 12 months, mean 140 mins per week at 75% Hrmax
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care with physical activity advice (UCwA)
Number of subjects: 50
Study: 26724782

Group type: EXPERIMENTAL
Intervention: Perampanel (n = 79)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 133
Study: 24913337

Group type: EXPERIMENTAL
Intervention: Adaptive Pacing Therapy (APT)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Specialist Medical Care (SMC)
Number of subjects: 641
Study: 22881827

Group type: EXPERIMENTAL
Intervention: Incredible Years program supplemented by positive strategies when reading with children
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Incredible Years program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 20520293

Group type: EXPERIMENTAL
Intervention: Ziprasidone (20-80 mg daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ziprasidone (nonaugmented group)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ziprasidone (augmented group)
Number of subjects: 62
Study: 18282663

Group type: EXPERIMENTAL
Intervention: VR alcohol cue environments
Number of subjects: 40

Group type: COMPARATOR
Intervention: VR neutral cue environments
Number of subjects: 40
Study: 16192477

Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (80 cGy each) plus antithymocyte globulin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Single dose of total‐body irradiation (200 cGy)
Number of subjects: 37
Study: 11867842

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Number of subjects: 102

Group type: COMPARATOR
Intervention: Immediate cord clamping (early group)
Number of subjects: 102
Study: 10534546

Group type: EXPERIMENTAL
Intervention: Dothiepin (up to 150 mg daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 7785952

Group type: EXPERIMENTAL
Intervention: Atraumatic Sprotte needle
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional Quincke needle
Number of subjects: 35
Study: 2127785

Group type: EXPERIMENTAL
Intervention: 3 million units of recombinant interferon alfa‐2b three times weekly for 24 weeks
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 1 million units of recombinant interferon alfa‐2b three times weekly for 24 weeks
Number of subjects: 166

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 3 million units of recombinant interferon alfa‐2b
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 1 million units of recombinant interferon alfa‐2b
Number of subjects: 166
Study: 493351

Group type: EXPERIMENTAL
Intervention: contract-relax
Number of subjects: 30

Group type: COMPARATOR
Intervention: hold-relax
Number of subjects: 30

Group type: COMPARATOR
Intervention: control
Number of subjects: 30
Study: 31103128

Group type: EXPERIMENTAL
Intervention: Standard Biomechanical Taping (SBMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vector Correcting Dysfunction Technique 1 (VCDT 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vector Correcting Dysfunction Technique 2 (VCDT 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard Biomechanical Taping (SBMT) and Vector Correcting Dysfunction Techniques (VCDT 1 and VCDT 2)
Number of subjects: 0
Study: 27680013

Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg monotherapy (RM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard fluence PDT (SF-PDT) plus ranibizumab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reduced-fluence PDT (RF-PDT) plus ranibizumab
Number of subjects: 60
Study: 26359900

Group type: EXPERIMENTAL
Intervention: Deprexis (internet-based cognitive behavioural therapy programme)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 90
Study: 23828828

Group type: EXPERIMENTAL
Intervention: Medical Therapy (MT)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Acute Myocardial Infarction (AMI) during follow-up
Number of subjects: 611

Group type: COMPARATOR
Intervention: Previous AMI
Number of subjects: 611

Group type: COMPARATOR
Intervention: AMI during follow-up
Number of subjects: 611
Study: 20438039

Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 35
Study: 19027095

Group type: EXPERIMENTAL
Intervention: Large randomized clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metaanalysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium and aspirin therapy
Number of subjects: 0
Study: 17595259

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study: 14734000

Group type: EXPERIMENTAL
Intervention: F/T-PSA ratio >30% with T-PSA of 3-5.99 g/ml
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: F/T-PSA ratio <10% with T-PSA of 3-5.99 g/ml
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: F/T-PSA ratio >30% with T-PSA of 6-9.99 g/ml
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: F/T-PSA ratio <10% with T-PSA of 6-9.99 g/ml
Number of subjects: 1385
Study: 11213866

Group type: EXPERIMENTAL
Intervention: Automated telephone disease management (ATDM) with telephone nurse follow-up
Number of subjects: 272

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 272
Study: 9810957

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP nasal spray)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 7697840

Group type: EXPERIMENTAL
Intervention: 92‐kD gelatinase immunostaining in unstable angina patients (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 92‐kD gelatinase immunostaining in stable angina patients (n = 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Active synthesis of 92‐kD gelatinase in unstable angina patients (n = 10)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Active synthesis of 92‐kD gelatinase in stable angina patients (n = 10)
Number of subjects: 24
Study: 2647315

Group type: EXPERIMENTAL
Intervention: MQ-F-OK therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: FAM therapy
Number of subjects: 40
Study: 563620

Group type: EXPERIMENTAL
Intervention: Combination of ferrous sulfate (80 mg Fe++) and folic acid (350 microgram)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Ferrous sulfate (80 mg Fe++)
Number of subjects: 29
Study: 31349916

Group type: EXPERIMENTAL
Intervention: 42-day course of dexamethasone (0.5 mg/kg/day × 3 days followed by a slow taper, n=30)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 9-day course of dexamethasone (0.5 mg/kg/day followed by a rapid taper, n=29)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 42-day course of dexamethasone
Number of subjects: 59
Study: 26472632

Group type: EXPERIMENTAL
Intervention: Computerized cognitive remediation with concurrent meta-cognitive skills training (CCR + MST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computerized cognitive remediation alone (CCR)
Number of subjects: 0
Study: 25348519

Group type: EXPERIMENTAL
Intervention: BC-3781 (pleuromutilin antimicrobial agent)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Population PK model (three-compartment model with first-order elimination and nonlinear protein binding)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Covariate analyses
Number of subjects: 129
Study: 23390181

Group type: EXPERIMENTAL
Intervention: AD dementia prevalence in 2010
Number of subjects: 10800

Group type: EXPERIMENTAL
Intervention: Projected AD dementia prevalence in 2050
Number of subjects: 10800
Study: 21651908

Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil citrate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 19288084

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16671881

Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed Loading (DL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 12881823

Group type: EXPERIMENTAL
Intervention: Threshold inspiratory muscle trainer, twice every other day, with 3 sets of 10 loaded inspirations (40%‐60% of patients' maximal inspiratory pressure [Pimax]) over a 10‐week period
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 10390303

Group type: EXPERIMENTAL
Intervention: Streptokinase treatment
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 8758084

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether (3.2 mg/kg loading dose followed by 1.6 mg/kg daily)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intravenous quinine (20 mg/kg loading dose followed by 10 mg/kg every 8 h)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 160
Study: 1881978

Group type: EXPERIMENTAL
Intervention: Capsulated aspartame (400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenylalanine (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspartic acid (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6578752

Group type: EXPERIMENTAL
Intervention: Active dialysis
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sham dialysis
Number of subjects: 5
Study: 3907842

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cianopramine
Number of subjects: 40
Study: 30544716

Group type: EXPERIMENTAL
Intervention: Reduction in savory and sweet snack intake
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Changes in lifestyle or body weight during the first six months
Number of subjects: 50
Study: 27009752

Group type: EXPERIMENTAL
Intervention: Western-style diet (WD) supplemented with 2 g calcium carbonate/d for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Western-style diet (WD) supplemented with 1,25(OH)2D3 (0.5 μg/d) for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western-style diet (WD) supplemented with 1,25(OH)2D3 (0.5 μg/d) and 2 g calcium carbonate/d for 4 weeks
Number of subjects: 0
Study: 25551175

Group type: EXPERIMENTAL
Intervention: Text message appointment reminders plus thrice-weekly supportive, informational, and motivational text messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text message appointment reminders
Number of subjects: 0
Study: 23244093

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 45
Study: 20660224

Group type: EXPERIMENTAL
Intervention: 3 g high‐MW oat β‐glucan/d (2,210,000 g/mol)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: 4 g medium‐MW oat β‐glucan/d (850,000 g/mol)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: 3 g medium‐MW oat β‐glucan/d (530,000 g/mol)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: 4 g low‐MW oat β‐glucan/d (210,000 g/mol)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Wheat fiber cereal
Number of subjects: 345
Study: 18709307

Group type: EXPERIMENTAL
Intervention: Cooling by frozen gel packs applied in the axilla for 5 min before treatment
Number of subjects: 36
Study: 16132323

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional open distal gastrectomy (ODG)
Number of subjects: 28
Study: 12706612

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment (585 nm, 5-6 J/cm², 3 treatments at monthly intervals)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment
Number of subjects: 38
Study: 10483895

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 0
Study: 8945144

Group type: EXPERIMENTAL
Intervention: Psychological support group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 2014075

Group type: EXPERIMENTAL
Intervention: Low-dose oxytocin regimen (increases at intervals of not less than 60 minutes)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Traditional protocol (oxytocin increased every 20 minutes as required)
Number of subjects: 123
Study: 6804311

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 200 mg daily for 28 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 400 mg daily for 28 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cimetidine 1 g daily for 28 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30840040

Group type: EXPERIMENTAL
Intervention: AIM HI intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 202
Study: 28919386

Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) 400mg at the rate of 60mg/kg/min
Number of subjects: 66
Study: 26910613

Group type: EXPERIMENTAL
Intervention: Single-dose oral levofloxacin (500 mg)
Number of subjects: 206

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 206
Study: 24382030

Group type: EXPERIMENTAL
Intervention: Chlorthalidone with amiloride
Number of subjects: 29

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 29
Study: 22039165

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of biomarkers
Number of subjects: 100
Study: 19131212

Group type: EXPERIMENTAL
Intervention: 10 g of wheat gluten hydrolysate (WGH)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 g of wheat gluten hydrolysate (WGH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0 g of wheat gluten hydrolysate (control)
Number of subjects: 30
Study: 17682989

Group type: EXPERIMENTAL
Intervention: Posaconazole (400 mg/day) for up to 6 months
Number of subjects: 20
Study: 14768918

Group type: EXPERIMENTAL
Intervention: Acupressure on Yintang
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Laserneedle acupuncture on Yintang
Number of subjects: 25
Study: 28291508

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 40 mg intravenous (group P, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (group S, n = 30)
Number of subjects: 60
Study: 10609905

Group type: EXPERIMENTAL
Intervention: Hypothermia (28 degrees C)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (32 degrees C)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Normothermia (37 degrees C)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: C3d release
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IgG fraction
Number of subjects: 45
Study: 7481548

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b treatment for 1 year
Number of subjects: 42

Group type: COMPARATOR
Intervention: Embolization of hepatic arteries
Number of subjects: 42
Study: 1929253

Group type: EXPERIMENTAL
Intervention: Cefprozil (500 mg once daily)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cefaclor (250 mg three times daily)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 94
Study: 6644347

Group type: EXPERIMENTAL
Intervention: High-dose interferon treatment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low-dose interferon treatment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Overall response
Number of subjects: 54
Study: 30115424

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 274
Study: 27217449

Group type: EXPERIMENTAL
Intervention: Enzastaurin 500 mg daily for 3 years
Number of subjects: 758

Group type: COMPARATOR
Intervention: Placebo for 3 years
Number of subjects: 758